Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022006133 - HISTONE-ACETYLATION-MODULATING AGENTS FOR THE TREATMENT AND PREVENTION OF ORGAN INJURY

Publication Number WO/2022/006133
Publication Date 06.01.2022
International Application No. PCT/US2021/039650
International Filing Date 29.06.2021
IPC
A01N 1/00 2006.1
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
1Preservation of bodies of humans or animals, or parts thereof
A01N 1/02 2006.1
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
1Preservation of bodies of humans or animals, or parts thereof
02Preservation of living parts
CPC
A61K 31/138
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines
135having aromatic rings ; , e.g. ketamine, nortriptyline
138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/19
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
19Carboxylic acids, e.g. valproic acid
A61K 31/585
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
58containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
585containing lactone rings, e.g. oxandrolone, bufalin
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Applicants
  • THE REGENTS OF THE UNIVERSITY OF MICHIGAN [US]/[US]
Inventors
  • CHEN, Yuqing E.
  • PITT, Bertram
  • LEI, Ienglam
  • TIAN, Shuo
  • PAGANI, Francis
  • TANG, Paul C.
  • WANG, Zhong
Agents
  • STAPLE, David W.
Priority Data
63/045,78429.06.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) HISTONE-ACETYLATION-MODULATING AGENTS FOR THE TREATMENT AND PREVENTION OF ORGAN INJURY
(FR) AGENTS DE MODULATION DE L'ACÉTYLATION DES HISTONES POUR LE TRAITEMENT ET LA PRÉVENTION D'UNE LÉSION D'UN ORGANE
Abstract
(EN) Provided herein are agents that modulate histone acetylation and pathways downstream thereof, and methods for the treatment and prevention of organ injury therewith. In particular, provided herein are combinations of histone deacetylase (HDAC) inhibitors, bromodomain and extraterminal-containing protein family (BET) inhibitors, promoters of histone acetyl transferase (HAT) activity, mineralocorticoid receptor (MR) antagonists, nuclear factor erythroid 2-related factor 2 (NRF2) activators, and/or aldehyde dehydrogenase (ALDH) agonists, and methods of use thereof for the treatment and prevention of heart injury.
(FR) L'invention concerne des agents qui modulent l'acétylation des histones et des voies en aval correspondantes, ainsi que des méthodes de traitement et de prévention d'une lésion d'un organe à l'aide de ceux-ci. En particulier, l'invention concerne des associations d'inhibiteurs d'histone désacétylase (HDAC), d'inhibiteurs de la famille des protéines à bromodomaine et à domaine extraterminal (BET), de promoteurs de l'activité de l'histone acétyl transférase (HAT), d'antagonistes du récepteur des minéralocorticoïdes (MR), d'activateurs du facteur 2 associé au facteur nucléaire érythroïde 2 (NRF2), et/ou d'agonistes de l'aldéhyde déshydrogénase (ALDH), ainsi que leurs méthodes d'utilisation pour le traitement et la prévention d'une lésion cardiaque.
Latest bibliographic data on file with the International Bureau